Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

By virtue of the notified transaction, EQT Fund Management S.à r.l. (“EFMS”), headquartered and registered in Luxembourg, intends to indirectly, acting as fund manager for and on behalf of the investment fund EQT IX (“EQT IX”), acquire sole control over the Cerba Group (“Cerba”), headquartered in France, within the meaning of Article 3(1)(b) of the EU Merger Regulation. The transaction will take place pursuant to a Put Option Agreement and a Share Transfer Agreement, and consists of a purchase of shares.

EQT IX was launched in July 2020 targeting commitments of approximately EUR 15 billion. EQT IX is an EQT investment fund that seeks to make investments primarily in Europe, with a focus on Northern Europe. EQT IX is a part of the EQT group of private equity funds ultimately owned by EQT AB, which is headquartered in Sweden. EQT IX has appointed EFMS as the alternative investment fund manager of EQT IX. EFMS has exclusive responsibility for the management of EQT IX. The EQT funds’ portfolio companies are active in a variety of industries and sectors, including in the pharmaceutical sector, in elderly care and veterinary services. For more information including on the sectors in which the EQT group of funds invest, please see www.eqtgroup.com.

Cerba is a global and diversified laboratory services company operating within clinical pathology in France and internationally. It is currently active in 40 countries across 5 continents. Cerba’s business activities are segmented into three main business lines: (i) specialty testing; (ii) routine testing and; (iii) clinical trial. It also offers veterinary biology and well-being services. Cerba has a diversified customer base which includes public and private hospitals, walk-in patients, physicians, pharmaceutical and biotech companies. For further information about Cerba, please refer to www.cerbahealthcare.com.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.